The rationale behind the U.S. Justice Department’s lawsuit against Optum and Amedisys (Nasdaq: AMED) is multi-faceted, citing potential adverse impacts on competition, home-based care workers and payers. Optum, a subsidiary of UnitedHealth Group (NYSE: UNH) in June 2023 penned its agreement to acquire Amedisys in an all-cash transaction of $101 per share, or about $3.3 billion. The transaction is expected to close this year. Last summer, DOJ began investigating potential antitrust concerns related to the deal, which culminated in a lawsuit filed last week. The state attorneys general of Maryland, Illinois, New Jersey, and New York are also plaintiffs in the suit.
Read the full article: Inside the Justice Department’s Amedisys-Optum Lawsuit //
Source: https://hospicenews.com/2024/11/18/inside-the-justice-departments-amedisys-optum-lawsuit